Mucocutaneous Disease Activity and Damage Accrual in Systemic Lupus Erythematosus: Analyses From the Asia-Pacific Lupus Collaboration Longitudinal Cohort Study - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Mucocutaneous Disease Activity and Accumulation of Damage in Systemic Lupus Erythematosus: Insights from the Asia-Pacific Lupus Collaboration Longitudinal Cohort Study

  • By

  • Amanda M. Saracino

  • Yanjie Hao

  • Dylan Hansen

  • Yi-Hsing Chen

  • Alberta Hoi

  • Vera Golder

  • Jiacai Cho

  • Aisha Lateef

  • Worawit Louthrenoo

  • Laniyati Hamijoyo

  • Shue Fen Luo

  • Yeong-Jian Jan Wu

  • Sandra Navarra

  • Leonid Zamora

  • Chak Sing Lau

  • Shirley Chan

  • Zhanguo Li

  • Hai-hong Yao

  • Sargunan Sockalingam

  • B. M. D. B. Basnayake

  • Yasuhiro Katsumata

  • Masayoshi Harigai

  • Zhuoli Zhang

  • Jun Kikuchi

  • Yuko Kaneko

  • Tsutomu Takeuchi

  • Madelynn Chan

  • Sang-Cheol Bae

  • Fiona Goldblatt

  • Sean O'Neill

  • Geraldine Hassett

  • Kristine Ng

  • Nicola Tugnet

  • Mark Sapsford

  • Yih Jia Poh

  • Michael Tee

  • Cherica Tee

  • Naoaki Ohkubo

  • Yoshiya Tanaka

  • Rangi Kandane-Rathnayake

  • Eric Morand

  • Shereen Oon

  • Mandana Nikpour

  • May 10, 2026

Share

Clinical Report: Assessment of Mucocutaneous Disease Activity in SLE

Overview

This study evaluates the prevalence of mucocutaneous disease activity and damage in systemic lupus erythematosus (SLE) using data from the Asia-Pacific Lupus Collaboration cohort. It highlights the association of mucocutaneous activity with health-related quality of life and the risk of damage accrual.

Background

Mucocutaneous manifestations are common in SLE, affecting 70% to 85% of patients and often leading to significant quality of life impairment. Despite their prevalence, these manifestations have been historically under-researched and under-treated.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

  • Mucocutaneous activity is prevalent in SLE, occurring in 70% to 85% of patients.
  • Persistent mucocutaneous activity is linked to a higher risk of damage accrual.
  • Health-related quality of life is significantly impacted by mucocutaneous manifestations.
  • White individuals may be at increased risk for mucocutaneous activity and damage.

Clinical Implications

Clinicians should prioritize the assessment and management of mucocutaneous disease activity in SLE patients to improve quality of life and reduce the risk of long-term damage. Early intervention may be critical in preventing the progression of mucocutaneous damage.

Conclusion

The findings underscore the importance of recognizing and addressing mucocutaneous manifestations in SLE to enhance patient care and outcomes.

Related Resources & Content

  1. Clinical Rheumatology, 2021 -- Factors Influencing and Protective Elements of Achieving Low Disease Activity in Systemic Lupus Erythematosus: Insights from a Prospective Study in a Chinese Population
  2. Frontiers in Pediatrics, 2026 -- Impact of high disease activity on damage accrual and disease outcomes in childhood-onset systemic lupus erythematosus
  3. Arthritis Care & Research, 2023 -- Discordance Between Systemic Lupus Erythematosus Disease Activity Index Domain Weights and Their Association With Organ Damage Accrual
  4. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus - PubMed
  5. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update | Annals of the Rheumatic Diseases
  6. Clinical Rheumatology — Factors Influencing Disease Activity Improvement in Initially Hospitalized Systemic Lupus Erythematosus Patients: A Retrospective Multicenter Study of a Chinese Population
  7. Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials
  8. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
  9. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus - PubMed
  10. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update | Annals of the Rheumatic Diseases
  11. Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus | Dermatology | JAMA Dermatology | JAMA Network
  12. The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis - Susan Manzi, Jorge Sánchez-Guerrero, Naoto Yokogawa, Joerg Wenzel, Josephine C Ocran-Appiah, Julia HN Harris, Munther Khamashta, Bernard Rubin, Norma Lynn Fox, Roger A Levy, Victoria P Werth, 2025
  13. Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis - PubMed
  14. Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus
  15. SLICC Damage Index :SLICC
  16. 2021 DORIS definition of remission in SLE: final recommendations from an international task force - PMC

Original Source(s)

Mucocutaneous Disease Activity and Damage Accrual in Systemic Lupus Erythematosus: Analyses From the Asia-Pacific Lupus Collaboration Longitudinal Cohort Study

  • by Amanda M. Saracino, Yanjie Hao, Dylan Hansen, Yi-Hsing Chen, Alberta Hoi, Vera Golder, Jiacai Cho, Aisha Lateef, Worawit Louthrenoo, Laniyati Hamijoyo, Shue Fen Luo, Yeong-Jian Jan Wu, Sandra Navarra, Leonid Zamora, Chak Sing Lau, Shirley Chan, Zhanguo Li, Hai-hong Yao, Sargunan Sockalingam, B. M. D. B. Basnayake, Yasuhiro Katsumata, Masayoshi Harigai, Zhuoli Zhang, Jun Kikuchi, Yuko Kaneko, Tsutomu Takeuchi, Madelynn Chan, Sang-Cheol Bae, Fiona Goldblatt, Sean O'Neill, Geraldine Hassett, Kristine Ng, Nicola Tugnet, Mark Sapsford, Yih Jia Poh, Michael Tee, Cherica Tee, Naoaki Ohkubo, Yoshiya Tanaka, Rangi Kandane-Rathnayake, Eric Morand, Shereen Oon, Mandana Nikpour

  • May 10, 2026

Related Content

The mirror of illness: identity, embodiment, and clinical care in systemic sclerosis

Fine Particulate Matter Constituents, Ozone, and Systemic Lupus Erythematosus: A Large General-Population Cohort Analysis With Extended Quantile g-Computation

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.